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The National Institute for Health and Care Excellence (NICE) in England and Wales 
is currently piloting a process whereby decision problem meetings are held sev-
eral months before starting a technology appraisal, rather than approximately 10 
weeks after formal invitation for the manufacturer to submit evidence, per current 
protocol. In general, the purpose and outcomes of the meeting, involving the NICE 
team and representatives from the evidence research group (ERG), do not change 
other than happening earlier. However, the meeting does allow manufacturers and 
sponsors to signal potential regulatory developments during the appraisal, ahead 
of the submission, to indicate potential inclusion and handling of patient access 
scheme proposals. For the meeting, an outline is required to demonstrate how the 
manufacturer/sponsor intends to approach the decision problem. This outline is 
to include, but is not limited to: evidence sources to be used; evidence likely to 
become available during the appraisal and how this might be managed; the planned 
approach to disease and economic modelling; potential challenges in interpreting 
the evidence; proposed approach to handling of uncertainty. If adopted, there are 
several implications of this new process for manufacturers/sponsors: market access 
strategy will need to be considered earlier than currently, with implications for data 
availability and analyses, value story development, positioning and indications, 
etc; cost-effectiveness models and their base cases will need earlier definition and 
completion; intentions regarding patient access schemes must be made before sub-
mission; ERGs may be reviewing limited published evidence in fast-moving therapy 
areas;, manufacturer market access groups will require more information from 
clinical, regulatory, medical affairs, modellers, epidemiologists much sooner that 
they currently do. Therefore, this seemingly simple change of meeting date rela-
tive to time of submission has important implications for manufacturers beyond 
their market access teams that require careful consideration in terms of planning 
and communication.
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Irish legislation recognises the need to consider the cost-effectiveness of health 
services, both for new interventions and their opportunity cost. Ireland did not 
have an explicit cost-effectiveness threshold until a 2012 agreement between the 
pharmaceutical industry and government established a € 45,000/QALY threshold. 
It was agreed as part of a deal that provided cost savings on existing medications 
and only applies to pharmaceuticals: there is no official threshold for non-drug 
interventions. Drugs with cost-effectiveness ratios within the threshold are guar-
anteed reimbursement, whereas those exceeding the threshold may be approved 
following further negotiation. A number of drugs far exceeding the threshold have 
been reimbursed in Ireland in recent years. There are four reasons for concern 
regarding Ireland’s threshold. Firstly, as a price floor not a ceiling it offers only a 
weak constraint on the introduction of cost-ineffective interventions, which leaves 
little scope for positive net health benefit. Secondly, that the threshold only applies 
to drugs creates potential for inconsistencies whereby relatively cost-effective 
non-drug interventions may not necessarily be approved, leading to sub-opti-
mal resource allocation. Thirdly, the current threshold has no apparent empiri-
cal basis. Finally, recent efforts to determine the appropriate cost-effectiveness 
threshold in the UK have estimated a threshold of approximately £13,000/QALY. 
Assuming Ireland’s threshold should be broadly comparable, the current Irish 
threshold is most probably too high. Consequently, reimbursing new interven-
tions at and above the € 45,000/QALY threshold is likely to result in net harm, as 
new drugs produce less health than the interventions they displace. The failure 
of Ireland’s threshold to be empirically determined by the cost-effectiveness of 
services foregone means the requirements of current legislation are not being 
met and reimbursement decisions cannot be considered fully evidenced-based. 
It is likely the current threshold is excessive and will lead to systematic damage 
of the health system.
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BAckground: Observational studies have been one of the hallmarks for the devel-
opment of public health and health economics fields. It includes epidemiologic stud-
ies, evaluation of patterns of care, use of resources, cost of illness, analysis of safety 
and effectiveness of interventions from real world. However, there are different pat-
terns of requirements for ethics reviews concerning observational studies, including 
vastly available models of ethics systems among different countries. Therefore, 
the objective of this study is to evaluate the ethics system, regulations and guide-
lines concerning observational studies in the selected countries. Methodology: 
Guidelines and regulations from Brazil, Argentina, Japan, New Zealand, Australia, 
USA and UK were reviewed to evaluate the ethics system and available guiding 
principle for observational studies. Additionally, a literature review was performed 
in the database Medline and SciELO mesh using the terms “ethics”, “observational 
study” and “multicenter study” among other similar terms. results: In Brazil, 
same ethics regulation is applied for both interventional and observational projects, 
plus there is unsatisfactory ethics review timelines and duplicity of ethics review 
when considering multicenter studies. Specific pathways for multicenter studies 
are available only in New Zealand, Australia, USA and UK. For the exception of Brazil, 
other evaluated countries have specific guidelines, recommendations or regulations 
for observational studies. conclusions: Brazil and Argentina still have a lot of 
and governmental authorities, case studies and the latest publications in value-based 
assessment (VBA) was performed to summarise the current perception of RWD, and 
to identify the advantages and challenges of using RWD to support market access and 
reimbursement. Only 10 guidelines were found from 73 European HTA agencies or 
governmental authorities which cited RWD as a source for evidence. NICE acknowl-
edges the difficulties of generalising RCT results to clinical practice, and supports 
the capture and analysis of observational data. In addition, recent developments in 
VBA anticipate a greater scrutiny of attempts to model natural history in economic 
evaluations, which may be addressed by using longitudinal observational data. Case 
studies have shown economic evaluations based on RCT data may lack external 
validity, and may consequently produce inaccurate estimates of economic endpoints. 
There is a consensus that RWD are valuable in providing clinical practice evidence on 
treatment pathways, resource use, long-term natural history and true effectiveness. 
However, there are methodological challenges (such as lack of randomisation) to 
be addressed before RWD are widely accepted as a complement to RCTs to support 
decision-making. RWD are increasingly recognised as a valuable source of evidence 
for market access and reimbursement, and as a complement to clinical trial evidence. 
Nevertheless, there are challenges that need to be addressed to ensure real world data 
provide valid evidence to the decision process.
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Combinations of high-cost branded drugs are becoming a reality. The synergistic 
value of combining two potent drugs is expected to considerably bolster the benefit 
to the patient in terms of efficacy and, in some cases, even safety. However, the syn-
ergistic cost of using branded combinations increases exponentially due to longer 
treatment durations, thus making the total treatment cost unaffordable to European 
health systems. This poster aims to explore the pricing and reimbursement issues 
that health systems will encounter during the evaluation of branded combination 
therapies and potential solutions to make these combinations affordable by the 
health care systems and ensure patient access to innovative drugs. To meet these 
objectives, an in-depth review of published sources was conducted, including a 
thorough analogue assessment. Moreover, targeted interviews with twenty payers 
involved at different levels of pricing and market access decision-making in the 
EU5 were also conducted to support analysis. Research revealed that synergistic 
costs of already expensive monotherapies, further exacerbated by longer duration 
of treatment, exceed payers’ cost thresholds. Therefore, on one hand payers will 
struggle to award a value-based price for the individual drugs as well as for the 
combination and will look to discount and/or restrict access. On the other hand, as 
this approach will not reflect the combination’s synergistic value and could threaten 
the life-cycle indications of each compound, manufacturers may not launch in some 
markets, thus, limiting patient access. Consequently, it is important to find a balance 
in setting a value-based price for individual indications and for the combinations 
to ensure broad patient access. Aligning patient, payer and manufacturer needs is 
paramount to find a win-win-win solution. In the context of brand-on-brand combi-
nations, traditional pricing models are not the solution and alternative approaches 
need to be adopted.
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BAckground: Knowledge of payer evidence requirements is vital to manufac-
turers who are facing increasing development costs for uncertain market access 
outcomes. Failure to engage payers early in asset development could result in delay 
of approval and/or coverage. oBjectives: Build the case for early payer engage-
ment as a means of reconciling the needs of payers and manufacturers Methods: 
A literature search was performed and primary research with key opinion leaders 
in the US and EU was conducted to characterize 5 early engagement strategies 
(informal consultation, formal consultation, outcomes-based risk sharing, financial-
based risk sharing, and formal partnerships). 7 major markets (Canada, France, 
Italy, Germany, Spain, UK, and US) were also assessed for their historic use of early 
engagement models. results: Payers want more manufacturer involvement in evi-
dence development, including input into clinical trial design and RWE development 
in phases II and III through formal and informal consultations. Articulation of an 
asset’s value story in the peri-launch phase and negotiations with regional and local 
payers through direct consultations allows manufacturers to position the asset for 
optimal pricing and reimbursement. When agreement cannot be reached on price 
or reimbursement terms, risk-sharing agreements allow broader access in exchange 
for the manufacturer bearing incrementally greater financial risk. Manufacturers 
have also built partnerships to uncover the real-world value of therapies and gain 
insight into usage and adherence patterns. Each market has its own challenges 
for promoting collaboration, requiring manufacturers to tailor their approach to 
the various national and local payers conclusion: Early planning is imperative 
in value-focused health care. When early payer engagement succeeds, it provides 
manufacturers time to design informed strategies to meet payer valuation needs. 
Evidence development that is closely aligned with payer requirements results in 
therapies that are more cost effective and gain quicker market access, benefitting 
manufacturers, payers, and patients alike.
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